<DOC>
	<DOCNO>NCT01381679</DOCNO>
	<brief_summary>This non-interventional longitudinal study follow-up Austrian Cholesterol Screening Treatment project ( ACT I ) , assess cholesterol status , include achievement target level applicable time ( LDL level &lt; 100 mg/dL ) , participant coronary heart disease ( CHD ) already treat statin . In study , participant without adequate LDL-cholesterol reduction statin underwent extension therapy ezetimibe goal achieve target level .</brief_summary>
	<brief_title>Effect Ezetimibe Treatment Low-density Lipoprotein Cholesterol ( LDL-C ) Levels Participants With Coronary Heart Disease ( CHD ) Already Treated With Statin ( MK-0653A-205 AM1 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Inclusion criterion : Participants LDLcholesterol target level achieve . Participants decision make physician initiate treatment ezetimibe ( longitudinal analysis ) . The treatment decision make prior independent inclusion participant study . Participants LDL cholesterol level â‰¤113 mg/dl high risk , lead casebycase approval medication may document . Exclusion criterion : Any condition , opinion treat physician , precludes treatment ezetimibe . In order interfere data collection recommend include participant currently clinical trial . Previous ongoing treatment ezetimibe .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>